Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Nicole Basset‐Séguin(Université Paris Cité), Johan Hansson(Karolinska Institutet), Axel Hauschild(University Hospital Schleswig-Holstein), Lisa Licitra(University of Milan), Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob(Aix-Marseille Université), B. Guillot(Université de Montpellier), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), D. Scott Ernst, Laurent Mortier, L. Thomas(University of Liverpool), Rainer Kunstfeld(Vienna General Hospital), Reinhard Dummer(University Hospital of Zurich), Sarah Williams(Ruhrlandklinik), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Brigitte Dréno(Nantes Université), Ioannis Xynos(AstraZeneca (United Kingdom)), A. Fittipaldo(Roche (United Kingdom))
Cited by 244
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k